Greenwoods Asset Management Hong Kong Ltd. Has $1.97 Million Position in Pfizer Inc. (NYSE:PFE)

Greenwoods Asset Management Hong Kong Ltd. reduced its stake in Pfizer Inc. (NYSE:PFE) by 19.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 74,200 shares of the biopharmaceutical company’s stock after selling 18,400 shares during the period. Greenwoods Asset Management Hong Kong Ltd.’s holdings in Pfizer were worth $1,969,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Callan Family Office LLC acquired a new position in shares of Pfizer in the fourth quarter valued at $595,000. Candriam S.C.A. boosted its position in shares of Pfizer by 7.7% in the fourth quarter. Candriam S.C.A. now owns 422,501 shares of the biopharmaceutical company’s stock valued at $11,209,000 after acquiring an additional 30,207 shares during the period. Ethos Financial Group LLC boosted its position in shares of Pfizer by 21.9% in the fourth quarter. Ethos Financial Group LLC now owns 11,390 shares of the biopharmaceutical company’s stock valued at $302,000 after acquiring an additional 2,044 shares during the period. Inceptionr LLC bought a new stake in shares of Pfizer in the fourth quarter valued at about $229,000. Finally, Raymond James Financial Inc. bought a new stake in shares of Pfizer in the fourth quarter valued at about $274,694,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by insiders.

Pfizer Stock Up 1.0 %

Shares of NYSE PFE opened at $26.21 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market cap of $148.51 billion, a price-to-earnings ratio of 18.59, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a 50-day moving average price of $26.30 and a two-hundred day moving average price of $27.26.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the previous year, the firm earned $0.10 earnings per share. The business’s quarterly revenue was up 24.7% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.56%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is currently 121.99%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Citigroup reduced their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.